Immuno-oncology Focus RXi is building next-generation immuno-oncology therapeutics using its self-delivering RNAi sd-rxRNA platform, presenting a targeted opportunity to engage BD teams around novel IO modalities and potential collaboration on RNAi-based therapies.

RNAi Platform Value The core sd-rxRNA technology indicates potential partnerships in drug discovery and development, especially with teams seeking delivery-enabled RNAi solutions to enhance potency, persistence, and cell-type targeting.

Academic Interest Recent and ongoing scientific communications with Keystone Symposia and related RNAi/non-coding RNA venues suggest a pathway to engage researchers and academic collaborators for joint research programs or sponsored studies.

Public Growth Path RXi’s journey from public offering to commercialization indicates readiness to explore strategic alliances with larger biotechs or CROs for late-stage development, manufacturing partnerships, or licensing of sd-rxRNA assets.

Financial Signals Revenue is in the modest range, signaling openness to co-development, milestone-driven partnerships, or upfronts with risk-sharing structures to accelerate pipeline progression while aligning with potential buyers or strategic partners.